On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, based on...
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
In a retrospective national VA cohort of nearly 1 million Veterans, tobacco smoking duration criteria identified more screening-eligible patients and fewer missed lung cancer diagnoses than pack-year...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
In an integrated phase 2 analysis of HPV-associated oropharyngeal cancer, FMISO PET-guided chemoradiotherapy de-escalation was associated with 97% 5-year overall survival in both the 30-Gy and 70-Gy...
The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.
The FDA approved Enhertu for neoadjuvant treatment of adults with HER2-positive stage II or III breast cancer and adjuvant treatment of patients with residual invasive disease after neoadjuvant therapy.
...
